Factors influencing time to viral rebound during analytical treatment interruptions in HIV cure trials (AIDS 2024) - Jun 19, 2024 - Abstract #OAA0206LB; Pres time: Jul 23, 2024; 11:05 AM - 11:13 AM; Location: Room 13a/Channel 6; "The trials investigated the following interventions alone or in combination: broadly neutralizing antibodies (bNAb) (3BNC117, 10-1074), histone deacetylase inhibitors (HDACi) (romidepsin, panobinostat), HIV-1 peptide vaccine (Vacc-4x) and toll-like receptor 9 (TLR9) agonist (MGN1703). Our findings shed new light on factors influencing time to viral rebound as well as loss of virologic control. These findings can inform the design of novel cure trials but also highlight the potential impact of early bNAb treatment on virological control during ATI."
Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease • CD4
|
|
V. Klastrup1,2; J.D. Gunst1,2; T.A. Rasmussen1,2; M. Tolstrup1,2; O.S. Soegaard1,2
|